From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy - the Bracknor Death Spiral explained Part 2 - this is just so bad, it is awful.

By Tom Winnifrith, The Sheriff of AIM | Wednesday 22 February 2017


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have noted before that some death spirals are in fact a decent way for companies to raise cash, cheaper and less share price destructive than a bucket shop placing. But the Bracknor deal announced today by Advanced Oncotherapy (AVO), which had promised non dilutive funding but clearly does not mean a word it says, as I explained here earlier, is a total rotter. It will crater the share price as Bracknor makes a killing. Let me explain why.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 23:31:11